Immix Biopharma is a clinical-stage biopharmaceutical company developing chimeric antigen receptor cell therapy (CAR-T) treatments for light chain amyloidosis and other serious diseases. The company's lead product, NXC-201, is an autologous CAR-T engineered via proprietary platform technologies to target and eliminate diseased plasma cells in amyloidosis patients, with the program supported by multiple regulatory designations including Breakthrough Therapy, Orphan Drug, and Regenerative Medicine Advanced Therapy designations. The company is pre-commercial and plans to generate revenue through product sales, royalty payments to its technology licensors, regulatory milestone payments, and grant funding, while competing against major pharmaceutical firms in the amyloidosis treatment market.